{"article_title": "The FDA's Black Lung", "article_keywords": ["slow", "scarring", "drug", "terminal", "suffering", "tissue", "black", "usually", "lung", "targets", "fdas", "wait"], "article_url": "http://www.wsj.com/articles/SB10001424052702304709904579409163556018566", "article_text": "Government power can ruin fortunes, reputations and businesses, but at least the targets usually escape with their lives. Not so with the Food and Drug Administration, whose culture of political control is often lethal. This reality is all too familiar for the 200,000 or so Americans suffering from a terminal lung disorder as they wait, and wait, and wait for the FDA to approve a good drug that can slow the progression of their disease.\n\nIdiopathic pulmonary fibrosis is the scarring of lung tissue over time with no known...", "article_metadata": {"article.template": "snippet", "article.created": "2014-03-02T23:11:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "The agency barred a drug that could help patients with pulmonary fibrosis, the Wall Street Journal writes in an editorial.", "title": "The FDA's Black Lung", "image": {"src": "https://si.wsj.net/public/resources/images/BN-BS947_3fda_G_20140302172159.jpg", "alt": "The FDA's Black Lung: The agency barred a drug that could help patients with pulmonary fibrosis.", "identifier": "https://si.wsj.net/public/resources/images/BN-BS947_3fda_D_20140302172159.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB10001424052702304709904579409163556018566&headline=The%20FDA%26apos%3Bs%20Black%20Lung%3A%20The%20agency%20barred%20a%20drug%20that%20could%20help%20patients%20with%20pulmonary%20fibrosis.&weburl=http://www.wsj.com/articles/SB10001424052702304709904579409163556018566"}}, "page.site.product": "WSJ", "keywords": "regulation,government policy,regulatory bodies,new products,services,research,development,new product approvals,corporate,industrial news,political,general news,politics,international relations,domestic politics,government bodies,executive branch,health,human services department,editorials,pharmaceuticals,health care,life sciences", "news_keywords": "regulation,government policy,regulatory bodies,new products,services,research,development,new product approvals,corporate,industrial news", "article.headline": "The FDA's Black Lung: The agency barred a drug that could help patients with pulmonary fibrosis.", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-BS947_3fda_E_20140302172159.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-BS947_3fda_D_20140302172159.jpg"}}, "description": "The agency barred a drug that could help patients with pulmonary fibrosis, the Wall Street Journal writes in an editorial.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB10001424052702304709904579409163556018566&headline=The%20FDA%26apos%3Bs%20Black%20Lung%3A%20The%20agency%20barred%20a%20drug%20that%20could%20help%20patients%20with%20pulmonary%20fibrosis.&weburl=http://www.wsj.com/articles/SB10001424052702304709904579409163556018566", "user.type": "nonsubscriber", "article.page": "Opinion", "page.content.format": "responsive", "article.summary": "The agency barred a drug that could help patients with pulmonary fibrosis, the Wall Street Journal writes in an editorial.", "page.site": "wsj", "testkeys": "C", "article.published": "2014-03-02T23:11:00.000Z", "dj.asn": "i-75fe", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"embed_count": 1, "image_count": 1, "word_count": 543, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "The agency barred a drug that could help patients with pulmonary fibrosis, the Wall Street Journal writes in an editorial.", "title": "The FDA's Black Lung", "url": "http://www.wsj.com/articles/SB10001424052702304709904579409163556018566", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-BS947_3fda_G_20140302172159.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "The FDA\u2019s Black Lung", "article.type": "Review & Outlook (U.S.)", "article.id": "SB10001424052702304709904579409163556018566", "user.exp": "default", "article.updated": "2014-03-02T23:11:00.000Z"}, "_id": "\"57477af36914bd0286fcdbf5\"", "article_summary": "Idiopathic pulmonary fibrosis is the scarring of lung tissue over time with no known...\nGovernment power can ruin fortunes, reputations and businesses, but at least the targets usually escape with their lives.\nThis reality is all too familiar for the 200,000 or so Americans suffering from a terminal lung disorder as they wait, and wait, and wait for the FDA to approve a good drug that can slow the progression of their disease.\nNot so with the Food and Drug Administration, whose culture of political control is often lethal."}